InsiderTrades.com logo
George M. Jenkins net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

George Jenkins Biography and Net Worth

Director of Palvella Therapeutics

From 1987 to 2005, Mr. Jenkins was a general partner of Apax Partners, a leading global private equity firm where he served as chief operating officer overseeing a multi-billion dollar venture capital and private equity investment portfolio. Since 2006, Mr. Jenkins has been an active private investor primarily funding technology-based start-ups. Mr. Jenkins has been or currently serves as a board member of numerous public and private companies, including SkinMedica (acquired by Allergan), Colorescience, Flower Orthopedics, Power Survey, Sunglass Hut, and Spyder Active Sports. Prior to joining Apax, Mr. Jenkins was a banker managing banking facilities in Europe. Mr. Jenkins earned a B.A. in Economics and Accounting from Lafayette College where he currently serves as a Trustee.

What is George M. Jenkins' net worth?

The estimated net worth of George M. Jenkins is at least $17.18 million as of April 9th, 2025. Jenkins owns 183,171 shares of Palvella Therapeutics stock worth more than $17,181,440 as of December 5th. This net worth approximation does not reflect any other assets that Jenkins may own. Learn More about George M. Jenkins' net worth.

How do I contact George M. Jenkins?

The corporate mailing address for Jenkins and other Palvella Therapeutics executives is 225 Franklin Street 26th Floor, Boston MA, 02110. Palvella Therapeutics can also be reached via phone at 857-246-8998 and via email at [email protected]. Learn More on George M. Jenkins' contact information.

Has George M. Jenkins been buying or selling shares of Palvella Therapeutics?

George M. Jenkins has not been actively trading shares of Palvella Therapeutics within the last three months. Most recently, on Wednesday, April 9th, George M. Jenkins bought 2,500 shares of Palvella Therapeutics stock. The stock was acquired at an average cost of $20.13 per share, with a total value of $50,325.00. Following the completion of the transaction, the director now directly owns 183,171 shares of the company's stock, valued at $3,687,232.23. Learn More on George M. Jenkins' trading history.

Are insiders buying or selling shares of Palvella Therapeutics?

In the last twelve months, Palvella Therapeutics insiders bought shares 2 times. They purchased a total of 6,500 shares worth more than $102,045.00. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 4,302 shares worth more than $370,961.46. The most recent insider tranaction occured on November, 19th when COO Kathleen Goin sold 4,302 shares worth more than $370,961.46. Insiders at Palvella Therapeutics own 20.5% of the company. Learn More about insider trades at Palvella Therapeutics.

Information on this page was last updated on 11/19/2025.

George M. Jenkins Insider Trading History at Palvella Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/9/2025Buy2,500$20.13$50,325.00183,171View SEC Filing Icon  
12/18/2024Buy4,000$12.93$51,720.00180,671View SEC Filing Icon  
See Full Table

George M. Jenkins Buying and Selling Activity at Palvella Therapeutics

This chart shows George M Jenkins's buying and selling at Palvella Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Palvella Therapeutics Company Overview

Palvella Therapeutics logo
Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.
Read More

Today's Range

Now: $93.80
Low: $90.09
High: $95.00

50 Day Range

MA: $79.06
Low: $59.59
High: $102.79

2 Week Range

Now: $93.80
Low: $11.17
High: $106.71

Volume

198,380 shs

Average Volume

244,702 shs

Market Capitalization

$1.11 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A